Jun. 25 at 2:41 PM
Biotech is starting to feel like one of those āunder-owned but inevitableā themes again.
$BEAM and a few others in the gene editing space are quietly getting more interesting as AI + computational biology + quantum research tools start compressing discovery timelines.
The way Iām looking at it, this isnāt just incremental drug development anymore, itās a shift toward programmable biology at scale.
If these toolchains keep improving, youāre talking about faster paths toward cancer treatment breakthroughs, neuroregeneration research, and maybe even slowing age-related decline over the long arc.
Still early, still volatile, but the direction of travel is clear: biotech is turning into an AI-powered discovery engine, not just a lab science trade.
